About PTCL Hematology-Oncology Intelligence Zone

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period August 22, 2025 through August 25, 2027, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the activity, totaling 3.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

3.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent developments in novel targets and treatments have advanced the management of peripheral T-cell lymphoma

Release Date

August 22, 2025

Expiration Date

August 22, 2027

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with PTCL, including oncologists, hematologists, and related clinicians.

Registration

Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This activity is supported by an independent medical education grant from Secura Bio.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Steven Horwitz, MD
Associate Attending, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Consultant: Auxilius Pharma; Abcuro; Corvus Pharmaceuticals; Daiichi Sankyo; Dren Bio; Kyowa Hakko Kirin; March Biosciences; ONO Pharmaceutical Co.; Pfizer Inc.; Secura Bio, Inc.; SymBio Pharma USA, Inc.; and Takeda Pharmaceutical Company

Research Support: ADC Therapeutics; Affimed; Celgene Corporation; CRISPR Therapeutics; Daiichi Sankyo; Kyowa Hakko Kirin; Seattle Genetics, Inc.; Takeda Pharmaceutical Company; Trillium Therapeutics Inc.; and Secura Bio, Inc.

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil
Associate Professor of Haematology
Oxford University and Lead of the Haematology and Lymphoma Service
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Beigene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Astra Zeneca: Consultancy, Honoraria, Research Funding; Pfizer: Research Funding; Amgen: Research Funding; BMS: Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau

Neha Mehta-Shah, MD
Associate Professor of Medicine, Division of Oncology
Siteman Cancer Center
WashU Medicine
Washington University
St. Louis, MO

Institutional clinical trial funding from AstraZeneca, Bristol-Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Secura Bio/ Verastem, Yingli Pharmaceuticals, Morphosys/Novartis, SeaGen, and Dizal Pharmaceuticals. Copmensation for service as a consultant for AstraZeneca, Secura Bio/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Janssen Karyopharm Therapeutics, Kyowa Hakko Kirin, Ono Pharmaceuticals, Pfizer, and Autolus.

Christina Poh, MD
Physician, Fred Hutch Cancer Center
Assistant Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Seattle, WA

Research Funding: Incyte Morphosys, Dren Bio

Consultancy: Incyte Morphosys, Acrotech, Seagen, Beigene

Program Managers and Web Editor Disclosure

Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

Recognize the clinical and pathologic features of PTCL
Utilize molecular and biomarker testing for diagnosis and prognosis
Apply current NCCN and international guidelines for PTCL management
Optimize treatment for both newly diagnosed and R/R PTCL/HF-L
Integrate targeted therapy into clinical practice
Understand indications for combination strategies in PTCL
Identify optimal dosing strategies for targeted therapies
Differentiate the role of epigenetic therapies in PTCL

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

ACCESS RESOURCES AND TRIALS
IN PTCL THERAPY

ABOUT THIS PROGRAM AND FACULTY DISCLOSURES